Christine Zedelmayer Sells 86,012 Shares of Equillium (NASDAQ:EQ) Stock

Key Points

• Equillium COO Christine Zedelmayer sold 86,012 shares on May 28 at an average price of $2.80, totaling about $240,834. The sale was made under a pre-arranged Rule 10b5-1 plan, and her ownership fell by nearly 58%.
• Equillium’s stock rose to $2.90 in recent trading on above-average volume, but the company remains volatile with a small market cap and a wide 52-week range of $0.27 to $3.10.
• Analyst sentiment is mixed but generally constructive: Leerink Partners upgraded the stock to outperform with a $6 target, while Roth Mkm reiterated a buy rating with a $12 target. The company also faces ongoing scrutiny after its latest earnings missed estimates.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 86,012 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $2.80, for a total value of $240,833.60. Following the sale, the chief operating officer owned 62,586 shares in the company, valued at $175,240.80. The trade was a 57.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The stock was sold at an average price of $2.70, for a total value of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total transaction of $362,438.00.

Equillium Price Performance

Shares of EQ stock traded up $0.06 during trading hours on Friday, reaching $2.90. The stock had a trading volume of 853,917 shares, compared to its average volume of 480,896. The firm has a market capitalization of $183.37 million, a PE ratio of -9.06 and a beta of 1.67. The firm has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $1.63. Equillium, Inc. has a twelve month low of $0.27 and a twelve month high of $3.10.

Equillium (NASDAQ:EQ - Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). On average, equities analysts anticipate that Equillium, Inc. will post -0.24 earnings per share for the current year.

More Equillium News

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Analyst Ratings Changes

Several analysts recently commented on the company. Roth Mkm restated a "buy" rating and issued a $12.00 target price on shares of Equillium in a research report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Equillium in a research report on Friday, March 27th. Cantor Fitzgerald assumed coverage on Equillium in a research note on Tuesday, April 7th. They issued an "overweight" rating and a $10.00 price target for the company. Stifel Nicolaus set a $5.00 price target on Equillium in a report on Thursday. Finally, Oppenheimer started coverage on shares of Equillium in a research note on Thursday, April 23rd. They set an "outperform" rating and a $7.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $7.57.

Institutional Investors Weigh In On Equillium

Several institutional investors have recently bought and sold shares of EQ. Dimensional Fund Advisors LP acquired a new stake in Equillium in the first quarter worth about $31,000. Virtu Financial LLC lifted its holdings in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company's stock worth $34,000 after purchasing an additional 13,591 shares during the period. Millennium Management LLC bought a new position in Equillium during the 3rd quarter valued at $35,000. Persistent Asset Partners Ltd bought a new position in Equillium during the 3rd quarter valued at $99,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Equillium during the 1st quarter valued at $100,000. Institutional investors and hedge funds own 27.05% of the company's stock.

About Equillium

Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.